Healthcare Hedge Fund Rhenman Rises 12 Per Cent This Year, As Biotech And Pharma Bets Drive June Returns
Healthcare hedge fund Rhenman rises 12 per cent this year, as biotech and pharma bets drive June returns Submitted By Hugh Leask | 12/07/2021 - 12:14pm Healthcare-focused equity hedge fund Rhenman & Partners scored a near-12 per cent return in the first six months of the year, as a number of correct calls in biotechnology and pharmaceuticals stocks drove gains in June. The Stockholm-based manager’s flagship strategy rose 5 per cent last month overall.
In this article
No tags related to this article.